ProQR Therapeutics Gets BofA Buy Initiation After Positive AX-0810 Phase 1 Data

AX-0810 Phase 1 shows dose-dependent bile acid increases and no serious adverse events, delivering the first human proof of concept for ProQR’s Axiomer RNA editing.